ArticleInternational journal of women's health2025
MiR-484 Regulates the IL-6/STAT3 Signaling Pathway by Down-Regulating KLF12 to Inhibit the Malignant Progression of Cervical Cancer.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate the function of miR-484 in C33A cells, as well as its mechanism. Methods: The mRNA expression patterns of miR-484 and Krüppel-like factor 12 (KLF12) in C33A cells were detected by quantitative reverse transcription polymerase chain reaction. MiR-484 mimics and miR-484 negative controls were transfected into C33A cells. Luciferase reporter assay was used to confirm the binding of miR-484 and KLF12. The effects of miR-484 on cell viability, migration, invasion, and apoptosis were assessed using the cell counting kit-8 assay, wound healing assay, Transwell assay, flow cytometry, and Western blot. Rescue experiments were performed by overexpressing KLF12. Western blot was utilized to examine the expression of KLF12, interleukin-6 (IL-6), Janus Kinase 2, phosphorylated-Janus Kinase 2, signal transducer and activator of transcription 3 (STAT3), and phosphorylated-STAT3 proteins. Results: MiR-484 expression was down-regulated in C33A cells, while KLF12 was up-regulated. The luciferase reporter assay confirmed the direct binding of miR-484 to KLF12. MiR-484 inhibited the proliferation, migration, and invasion of C33A cells while promoting apoptosis. Additionally, it could inhibit the expression of KLF12 protein and the activation of the IL-6/STAT3 signaling pathway. However, KLF12 overexpression could reverse the above effects. Conclusion: MiR-484 can specifically inhibit the KLF12-mediated IL-6/STAT3 signaling pathway, thereby suppressing the malignant biological behavior of C33A cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.